Cumulative Use of Anticholinergic Medication Tied to Dementia

This article originally appeared here.
Share this content:
Cumulative Use of Anticholinergic Medication Tied to Dementia
Cumulative Use of Anticholinergic Medication Tied to Dementia

TUESDAY, Jan. 27, 2015 (HealthDay News) -- Higher cumulative use of anticholinergics may increase the risk of dementia, according to a new study published online Jan. 26 in JAMA Internal Medicine.

Shelly Gray, Pharm.D., of the Group Health Research Institute-University of Washington in Seattle, and colleagues tracked outcomes for 3,434 seniors who were followed for more than seven years. Gray's group found that people who took at least 10 mg per day of doxepin (Sinequan), 4 mg per day of diphenhydramine (Benadryl), or 5 mg per day of oxybutynin (Ditropan) for more than three years were at greater risk for developing dementia.

In an institute news release, Gray said that "older adults should be aware that many medications -- including some available without a prescription, such as over-the-counter sleep aids -- have strong anticholinergic effects. And they should tell their health care providers about all their over-the-counter [medication] use."

However, "no one should stop taking any therapy without consulting their health care provider," Gray said. Instead, "health care providers should regularly review their older patients' drug regimens -- including over-the-counter medications -- to look for chances to use fewer anticholinergic medications at lower doses," she advised.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Trends in HIV/AIDS Have Worsened in African-Americans

Trends in HIV/AIDS Have Worsened in African-Americans

Action plan developed for community leaders that can reduce the disparity in HIV/AIDS

cfDNA Screening First for Trisomy 21 Doesn't Cut Miscarriage Rate

cfDNA Screening First for Trisomy 21 Doesn't Cut ...

Invasive testing if positive for trisomy 21 on cfDNA screen compared with immediate invasive testing

HPV Legislation Doesn't Impact Teen Sexual Behaviors

HPV Legislation Doesn't Impact Teen Sexual Behaviors

No substantive or significant associations between HPV legislation and adolescent sexual behaviors

is free, fast, and customized just for you!




Already a member?

Sign In Now »